RESEARCH

Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma

Hyung Min Kim1,2, Seok-Soo Byun3, Jung Kwon Kim3, Chang Wook Jeong4, Cheol Kwak4, Eu Chang Hwang5, Seok Ho Kang6, Jinsoo Chung7, Yong-June Kim8,9, Yun-Sok Ha10 and Sung-Hoo Hong11*

Abstract

Background: Renal cell carcinoma is characterized by a late recurrence that occurs 5 years after surgery; hence, continuous monitoring and follow-up is necessary. Prognosis of late recurrence of renal cell carcinoma can only be improved if it is detected early and treated appropriately. Therefore, tools for rapid and accurate renal cell carcinoma prediction are essential.

Methods: This study aimed to develop a prediction model for late recurrence after surgery in patients with renal cell carcinoma that can be used as a clinical decision support system for the early detection of late recurrence. We used the KOrean Renal Cell Carcinoma database that contains large-scale cohort data of patients with renal cell carcinoma in Korea. From the collected data, we constructed a dataset of 2956 patients for the analysis. Late recurrence and non-recurrence were classified by applying eight machine learning models, and model performance was evaluated using the area under the receiver operating characteristic curve.

Results: Of the eight models, the AdaBoost model showed the highest performance. The developed algorithm showed a sensitivity of 0.673, specificity of 0.807, accuracy of 0.799, area under the receiver operating characteristic curve of 0.740, and F1-score of 0.609.

Conclusions: To the best of our knowledge, we developed the first algorithm to predict the probability of a late recurrence 5 years after surgery. This algorithm may be used by clinicians to identify patients at high risk of late recurrence that require long-term follow-up and to establish patient-specific treatment strategies.

Keywords: Renal cell carcinoma, Machine learning, ROC curve: KOrean Renal Cell Carcinoma, Late recurrence

Background

Renal cell carcinoma (RCC) accounts for approximately 90% of all renal malignancies; therefore, cancer of the kidney is commonly referred to as RCC. Kidney cancer is the ninth most common cancer in men, with an estimated 431,288 new cases and 179,368 cancer deaths worldwide in 2020 [1]. According to the Korea National Cancer Center statistics in 2018, the incidence of kidney cancer steadily increased from 1999 to 2018 [2]. However, these statistics also show that the incidence of RCC is not high compared with other cancers, but the mortality rate of RCC increased by 3.92% per year between 1975 and 2009 [3], and RCC is the second most lethal urologic malignancy [4].

Although other alternative treatments exist, surgery is the gold standard treatment according to guidelines [5–7]. Though radical nephrectomy is the primary
treatment, recently, partial nephrectomy has been used to preserve kidney function [8]. However, despite these treatments, cancer recurs in 20–40% of patients [9–11]. Most cases of RCC recurrence occur within 5 years of surgery, while 10% of cases recur after 5 years [12–14]. Therefore, continuous follow-up after surgery is essential for RCC patients.

One of the biological characteristics of RCC is late recurrence, which occurs 5 years after surgery [12]. Studies have been conducted to identify various factors that can significantly influence late recurrence in RCC [15–18]. However, these studies, which relied on traditional statistical methods such as logistic regression analysis and the Cox proportional-hazards model to identify risk factors, have not led the ability to accurately predict late recurrence of renal cell carcinoma.

Recently, with the development of computer technology, studies that apply machine learning and deep learning methods to large-capacity data, including medical fields, are being actively conducted [19–23]. In the medical field, machine learning has shown excellent performance when applied to cancer diagnosis [24–26]. If data are used by various machine learning techniques that combine and analyze the risk factors discovered in these studies, it is possible to predict late recurrence. In two previous studies, machine learning models for predicting early recurrence of RCC, within 5 years, showed good predictive performance with the area under the receiver operating characteristic curve (AUROC) values of 0.836 [27] and 0.840 [28], respectively. However, few studies have aimed to predict the late recurrence of RCC using machine learning techniques because the long-term follow-up of patients is challenging, late recurrence rate is only approximately 10%, and collecting enough data for analysis requires a long time.

In a previous study, data on patients with late recurrence was insufficient, and an algorithm to predict the probability of recurrence within 5 and 10 years was developed accordingly, although without distinguishing between early and late recurrence [27]. However, previous studies have demonstrated that the factors influencing early and late recurrence vary [12, 16]. Therefore, it is necessary to develop a model that is specifically designed for the accurate prediction of late recurrence. In addition, since late recurrence is very rare, it is difficult to track and collect case data within only a single institution.

In the present study, we developed an algorithm, using machine learning techniques to predict late recurrence after surgery using data of patients with RCC continuously collected from multiple institutional hospitals.

To the best of our knowledge, this is the first study to develop a model that predicts only late RCC recurrence that occurs 5 years after surgery. The algorithm was intended to help select patients at high risk of late recurrence for continuous monitoring to enhance early detection and appropriate treatment.

**Methods**

**Study population**
The KOran Renal Cell Carcinoma (KORCC) web-based database system was established to collect the data on basic demographic and clinicopathological characteristics of patients with RCC in Korea [29]. Eight hospitals participating in the KORCC study group contributed to an established large cohort of patients with RCC by adding all consecutive patients from 1990 to date. This database construction project has been approved by the Seoul National University Bundang Hospital Ethics Committee (IRB No.: B1202/145-102). We collected data regarding 9,598 patients with RCC and 205 variables from the KORCC database and performed data preprocessing according to our study protocol. Variables include demographic and clinicopathological characteristics. To protect patients' personal information, resident registration numbers and hospital numbers have been excluded. Detailed variable types and distributions can be viewed through database construction studies [29]. This study protocol was approved by the Institutional Review Board (IRB) of the Catholic University of Korea (IRB No. KC20ZIDI0966). Informed consent was waived by the IRB of Catholic University of Korea since this study was retrospective and blinding of the personal information in the data was performed. The present study was designed and conducted in accordance with the relevant guidelines and regulations of the ethical principles for medical research involving human subjects, as stated by the World Medical Association Declaration of Helsinki.

**Variable selection**
The following two-step process was performed to select the variables affecting late recurrence among the 205 variables. First, variables with a significant difference (P < 0.05) were selected between the non-recurrence and late recurrence groups using a t-test for continuous variables and a chi-squared test for categorical variables using statistical methods. In the first process, 18 variables were extracted as significant variables (see additional table in Additional File 1), and in the second process, seven clinically significant variables were selected based on the advice of urologists. The seven variables selected were tumor size, operation type, histologic type, operative methods, pathological tumor stage, pathological node stage, and lymphovascular invasion. A urologist with extensive experience in RCC surgery selected the final variable based on previous studies [15–18] and their clinical experience with following patients after surgery.
Data screening
We included 9397 patients who underwent surgical treatment out of a total of 9598 patients with RCC to construct a dataset for the analysis. Among the 9397 patients, 4240 patients with a follow-up period of fewer than 5 years, 1037 patients with early recurrence, and 1164 patients with missing values were excluded. The 2956 patients who remained consisted of 2767 patients without recurrence and 189 patients with late recurrence over a follow-up of more than 5 years.

Data splitting and SMOTE technique for imbalanced datasets
To train and evaluate the model, we split the data into two datasets: 70% for training and 30% for testing. In the training and test data, there were 140 (6.8%) and 49 (5.5%) patients with late recurrence, respectively, which was very low compared with the number of patients with non-recurrence (Table 1). Data imbalance is one of the problems in medical data analysis, and it occurs because the proportion of patients with specific cancer or disease is relatively small compared with normal patients in data collected at hospitals. Oversampling [30], undersampling [30], and synthetic minority oversampling technique (SMOTE) [31] are used as representative methods to resolve data imbalance. However, in oversampling, an overfitting problem occurs because of data duplication, and in undersampling, a large amount of information is lost [32]. SMOTE is also an oversampling method, but it solves imbalance by generating synthetic data rather than duplicating the data [31]. SMOTE has been previously applied to medical data with data imbalance problems [33, 34]. Given the data imbalance in the our study, we used the SMOTE technique to increase the late recurrence group to 50% of the training data, which resulted in a 1:1 ratio between the two groups (Table 1).

Model development and validation
We developed a model by applying eight representative machine learning techniques that showed excellent performance in classification problems in our dataset. The machine learning techniques used were support vector machine (SVM) [35], logistic regression [36], k-nearest neighbor (KNN) [37], naïve Bayes (NB) [38], random forest [39], gradient boost [40], AdaBoost [41], and extreme gradient boosting (XGBoost) [42]. We used a grid search algorithm [43] to optimize the hyperparameters used in the machine learning models, and in this case, we searched for optimal hyperparameters through 3-fold cross-validation to avoid overfitting. We measured the performance of each machine learning model in the hyperparameter obtained through the grid search and cross-validation. For validation, we calculated five parameters as follows: sensitivity, specificity, accuracy, AUROC, F1-score, and confusion matrix. The calculation method was as follows:

\[
\text{Sensitivity, Recall} = \frac{TP}{TP + FN},
\]

\[
\text{Precision} = \frac{TP}{TP + FP},
\]

\[
\text{Specificity} = \frac{TN}{TN + FP},
\]

\[
\text{Accuracy} = \frac{TP + TN}{TP + FP + TN + FN},
\]

and

\[
\text{F1-score} = \frac{2 \times \text{Precision} \times \text{Recall}}{\text{Precision} + \text{Recall}},
\]

where TP is the number of true late recurrences, TN is the number of true non-recurrences, FP is the number of false-positive late recurrences, and FN is the number of false non-recurrences.

For the final model, the model with the highest performance was selected based on the AUROC. In addition, TP, NP, FP, and NP were confirmed from the results of applying the test data to the final selected model through the confusion matrix. The entire process from variable selection to model development and validation is shown in Fig. 1. We used Python (version 3.7.6) for statistical analysis and algorithm development.

| Table 1 | Distribution of datasets before and after SMOTE application |
|---------|-------------------------------------------------------------|
| **Training set (n = 2069)** | **Non-recurrence group** | **Late recurrence group** | **Test set (n = 887)** | **Non-recurrence group** | **Late recurrence group** |
| Before | 140 (6.8%) | 1929 (93.2%) | 49 (5.5%) | 838 (94.5%) | 49 (5.5%) |
| After | 1929 (50.0%) | 1929 (50.0%) | | | |
**Results**

**Patient characteristics**

Table 2 shows the characteristics of the late recurrence and non-recurrence groups. The seven selected variables showed significant differences between the two groups. Regarding the operation type, the rate of partial nephrectomy was 51.7% in the non-recurrence group, which was slightly higher than that of radical nephrectomy (48.3%), but in the late recurrence group, the rate of radical nephrectomy was 82.0%, which was much higher than that of partial nephrectomy. Regarding the operative method, open and laparoscopic surgeries were similar at 44.1% and 38.0%, respectively, in the non-recurrence group, but in the late recurrence group, the rate of open surgery was notably high at 75.1%. The pathological tumor stages of 1a and 1b accounted for 86.3% of the total in the non-recurrence group, but 53.4% in the late recurrence group, and the remaining 46.6% were distributed in stages 2–4. The distributions of the remaining variables are presented in Table 2.

**Hyperparameter optimization**

We performed hyperparameter optimization for each machine learning model and used a grid search...
algorithm and cross-validation. The optimal parameter combinations were determined by exploring various hyperparameters, and the selected hyperparameters for each machine learning model are listed in Table 3. We first split the train dataset into three parts. Next, because hyperparameters found in unsplit datasets can cause overfitting problems, we compared the performance of the hyperparameters in Table 3 through grid search.

### Table 2 Baseline characteristics of the patients with RCC

| Variable                  | Late recurrence group (189 Patients) | Non-recurrence group (2767 Patients) | P-value |
|---------------------------|-------------------------------------|--------------------------------------|---------|
| Operation type            | <0.001                              |                                      |         |
| Radical nephrectomy       | 155 (82.0%)                         | 1336 (48.3%)                        |         |
| Partial nephrectomy       | 34 (18.0%)                          | 1431 (51.7%)                        |         |
| Operative method          | <0.001                              |                                      |         |
| Laparoscopic              | 29 (15.3%)                          | 1051 (38.0%)                        |         |
| HALS                      | 6 (3.2%)                            | 78 (2.8%)                           |         |
| Open                      | 142 (75.1%)                         | 1221 (44.1%)                        |         |
| Robotic                   | 12 (6.3%)                           | 417 (15.1%)                         |         |
| Pathological tumor stage  | <0.001                              |                                      |         |
| 1a                        | 52 (27.5%)                          | 1811 (65.4%)                        |         |
| 1b                        | 49 (25.9%)                          | 579 (20.9%)                         |         |
| 2a                        | 38 (20.1%)                          | 131 (4.7%)                          |         |
| 2b                        | 7 (3.7%)                            | 48 (1.7%)                           |         |
| 3a                        | 34 (18.0%)                          | 167 (6.0%)                          |         |
| 3b                        | 7 (3.7%)                            | 20 (0.7%)                           |         |
| 3c                        | 0 (0.0%)                            | 2 (0.1%)                            |         |
| 4                         | 2 (1.1%)                            | 9 (0.3%)                            |         |
| Pathological node stage   | 0.005                               |                                      |         |
| N0                        | 115 (60.8%)                         | 1169 (42.2%)                        |         |
| N1                        | 172 (91.0%)                         | 2345 (84.7%)                        |         |
| Histologic type           | 0.002                               |                                      |         |
| Clear cell                | 5 (2.6%)                            | 41 (1.5%)                           |         |
| Papillary                 | 4 (2.1%)                            | 222 (8.0%)                          |         |
| Chromophobe               | 0 (0.0%)                            | 3 (0.1%)                            |         |
| Collecting duct           | 8 (4.2%)                            | 156 (5.6%)                          |         |
| Lymphovascular invasion   | <0.001                              |                                      |         |
| No                        | 2701 (97.6%)                        |                                      |         |
| Yes                       | 17 (9.0%)                           |                                      |         |
| Tumor size (mm)           | 68.2±68.9                           | 38.8±27.6                           | <0.001  |

HALS hand-assisted laparoscopic surgery

### Table 3 Hyperparameter optimization using the grid search algorithm

| Algorithms   | Hyperparameters                                                                 |
|--------------|---------------------------------------------------------------------------------|
| Kernel SVM   | kernel: (linear, rbf)                                                            |
|              | C: (0.01, 0.1, 0.5, 1.0)                                                        |
|              | gamma: (0.01, 0.05, 0.1, 0.5, 1.0)                                              |
| Logistic     | Penalty: (L1, L2)                                                                |
| regression   | C: (0.001, 0.01, 0.1, 1.0, 10)                                                   |
| KNN          | n-neighbors: (2, 4, 6, 8, 10)                                                    |
| Naive Bayes  | alpha: (0, 0.1, 1, 5, 10, 20, 30)                                                |
| Random forest| n_estimators: (10, 50, 100, 150, 200)                                             |
|              | max_depth: (4, 8, 12, 16, 20)                                                    |
| Gradient boost| learning_rate: (0.05, 0.01, 0.005, 0.01)                                           |
|              | max_depth: (1, 3, 5, 7, 9, 12)                                                   |
| AdaBoost     | n_estimators: (10, 50, 100, 200, 500)                                            |
|              | learning_rate: (0.05, 0.01, 0.005, 0.001)                                        |
| XGBoost      | n_estimators: (10, 50, 100, 200, 500)                                            |
|              | learning_rate: (0.05, 0.01, 0.005, 0.001)                                        |
|              | max_depth: (1, 3, 5, 7, 9, 12)                                                   |

Penalty: Specify the norm used in the penalization (L1 = L1 regularization, L2 = L2 regularization); C, inverse of regularization strength; n-neighbors, number of neighbors; alpha, additive smoothing parameter (0 for no smoothing); n_estimators, number of trees; max_depth, maximum depth of the tree

SVM support vector machine, KNN k-nearest neighbour, XGBoost extreme gradient boosting

*Parameter finally selected through parameter optimization

### Table 4 Performance of the machine learning algorithms

| Model         | Sensitivity | Specificity | Accuracy | AUROC    | F1-score |
|---------------|-------------|-------------|----------|----------|----------|
| Kernel SVM    | 0.551       | 0.852       | 0.835    | 0.702    | 0.579    |
| Logistic      | 0.653       | 0.802       | 0.793    | 0.727    | 0.599    |
| regression    |             |             |          |          |          |
| KNN           | 0.408       | 0.881       | 0.855    | 0.644    | 0.587    |
| Naive Bayes   | 0.612       | 0.805       | 0.795    | 0.709    | 0.566    |
| Random forest | 0.490       | 0.834       | 0.815    | 0.662    | 0.566    |
| Gradient      | 0.531       | 0.868       | 0.849    | 0.699    | 0.576    |
| boost         |             |             |          |          |          |
| AdaBoost      | 0.673       | 0.807       | 0.799    | 0.740    | 0.609    |
| XGBoost       | 0.633       | 0.807       | 0.797    | 0.720    | 0.587    |

**Model performance in predicting late recurrence of RCC**

Performance was measured in parameters optimized for each machine learning model, and the results of the comparisons of sensitivity, specificity, accuracy, and AUROC are shown in Table 4. The model with the highest performance based on AUROC was AdaBoost. AdaBoost showed a predictive performance of 0.673 sensitivity, 0.807 specificity, 0.799 accuracy, 0.74 AUROC, and 0.609 F1-score.
The ROC curve for each model is shown in Fig. 2; AdaBoost has the highest AUROC (0.74). Next, performance was compared through the confusion matrix of AdaBoost, which had the highest performance, and logistic regression, which had the second-highest performance, as shown in Fig. 3. For FN, AdaBoost had 16, which was 1 less than for logistic regression (17), and for FP, AdaBoost had 162, which was 4 less than for logistic regression.
In addition, when comparing the F1-score, which is the performance seen together with AUROC when data imbalance exists, the logistic regression model shows 0.599 performance, while Adaboost shows a higher 0.609 performance.

Thus, AdaBoost showed the highest performance in classification accuracy compared with the other models, and we finally developed an algorithm using AdaBoost. In order to use the Adaboost model developed by us, the user first inputs patient data (e.g., operation type, operative method, pathological tumor stage, pathological node stage, histologic type, lymphovascular invasion, tumor size). In the final selected hyperparameters \( n_{\text{estimator}} = 500, \) learning rate \( = 0.05, \) max_depth \( = 3 \), the AdaBoost model returns a predicted value for the patient information input.

**Discussion**

In the current study, the data of 2956 patients with RCC collected from eight tertiary hospitals in Korea were analyzed. We successfully developed an algorithm to predict the likelihood of late recurrence in patients with RCC after surgery using seven clinicopathological factors. Of the eight machine learning models used, AdaBoost showed the best performance. Despite the powerful predictive ability of machine learning, the biggest drawback is that it is difficult for humans to interpret the final classification process through a complex structure [44]. However, tree-based models such as AdaBoost can measure feature importance using the Gini index [45] as it has the advantage of clarifying which variables have a high influence on prediction. The AdaBoost variable importance analysis showed that tumor size was the most important variable followed by surgery type, histologic type, operation type, pathological tumor stage, pathological node stage, and lymphovascular invasion, in that order (Fig. 4).

In patients with localized RCC, tumor size was shown to be significantly associated with survival and recurrence, with local recurrence-free survival significantly decreasing with each 1-cm increase in tumor size [46]. Our data showed that the average tumor size was significantly different between the late recurrence (68.2 mm) and non-recurrence (38.8 mm) groups. In the late recurrence group, the rates of radical nephrectomy and open surgery were 82% and 75.1%, respectively. However, in the non-recurrence group, similar rates were shown by radical nephrectomy, partial nephrectomy and by open and laparoscopic surgeries. In previous studies, patients with clear cell RCC had significantly poorer 5-year recurrence-free survival than patients with papillary RCC and chromophobe RCC (78% vs. 86% vs. 91%, \( P = 0.001 \)) [47]. In our data, the clear cell ratio was 91.0% in the late recurrence group and 84.7% in the non-recurrence group.
group, with a greater proportion in the late recurrence group. Pathologic tumor stage [12, 15, 18], pathologic node stage [17], and lymphovascular invasion [15], which had relatively low variable importance, have also been proven to be significant variables for late recurrence in various studies.

In previous studies, 10 variables (sex, age, body mass index, smoking status, pathological tumor stage, histologic type, necrosis, lymphovascular invasion, capsular invasion, and Fuhrman nuclear grade) were significant predictors of early recurrence [27]. However, seven variables (sex, age, body mass index, smoking, capsular invasion, Fuhrman nuclear grade, and necrosis) were non-significant (\(P > 0.05\)) in late recurrence prediction. Moreover, in our results, four variables (operation type, operative method, pathological node stage, and tumor size) were found to be significant variables for classifying both non-recurrence and late recurrence.

The 10-year recurrence prediction algorithm developed in the previous study included patients who recurred within 5 years [27]. In contrast, our study included only patients with RCC that recurred >5 years after surgery. Therefore it is difficult to directly compare the performance our new algorithms with those previously developed. Hence, a limitation of the study is that performance and time complex comparisons with related studies could not be carried out.

Although studies have been conducted to explore factors influencing late recurrence using statistical methods, our study is the first to develop a model that directly predicts late recurrence of RCC using machine learning. The reason for the scarcity of studies is that late recurrence occurs in only about 10% of cases, and after 5 years, necessitating a very long follow-up period; thus, it is difficult to collect sufficient data for machine learning analysis. In general, variable selection is applied after dataset splitting. However, in small datasets like ours, we found that significant variable selection varied depending on how the dataset was split. Considering this bias, we first selected variables using all data and then split the dataset. The KORCC group has continuously collected data from hospitals with the largest number of patients with RCC in Korea, and we were able to develop a predictive model using the collected data.

Since our data were collected from eight Korean hospitals, we present the results that reflect both internal and external verification. However, there is a limitation as we were unable to conduct additional external verification through the hospitals of other countries; our model was developed to suit the characteristics of patients with RCC in Korea. Therefore, performance cannot be guaranteed when applied to patients in other countries. Our model showed an AUROC of 0.74. An AUROC of 0.7 to 0.8 is indicative of an acceptable model, and if it exceeds 0.8, the model is considered excellent [48]. Machine learning shows better performance when provided with a large amount of data. In future studies, we aim to develop an excellent model with an AUROC \(\geq 0.8\) when more late recurrence patient data are available in the KORCC database.

Conclusions
We successfully developed an algorithm to predict late recurrence using the AdaBoost model, a machine-learning technique. The developed predictive model calculates the risk of late recurrence for each patient based on the collected data. This algorithm should help clinicians select patients who need a long-term follow-up of \(\geq 5\) years after surgery and to design treatment plans accordingly. In the future, it is necessary to improve and stabilize the model performance through additional external validation studies using larger samples.

**Abbreviations**
AUROC: Area under the receiver operating characteristic curve; FN: The number of false non-recurrences; FP: The number of false-positive late recurrences; IRB: Institutional Review Board; KNN: K-nearest neighbor; KORCC: KOrean Renal Cell Carcinoma; NB: Naïve Bayes; RCC: Renal cell carcinoma; SMOTE: Synthetic minority oversampling technique; SVM: Support vector machine; TN: The number of true non-recurrences; TP: The number of true late recurrences; XGBoost: Extreme gradient boosting.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12911-022-01964-w.

**Additional file 1** Results of the first variable selection process

**Acknowledgements**
We thank the KOrean Renal Cell Carcinoma (KORCC) group for assisting us with the data analysis.

**Author contributions**
Conceptualization: H.M.K. and S.-H.H. Methodology: S.-S.B., J.K.K., C.W.J., E.C.H., S.H.K., and S.-H.H. Software: H.M.K. Validation: J.C., C.K., Y.-J.K., Y.-S.H., and S.-H.H. Formal Analysis: H.M.K. Investigation: S.-S.B., J.K.K., C.W.J., E.C.H., S.H.K., J.C., C.K., Y.-J.K., and Y.-S.H. Data curation: S.-H.H. Writing—Original Draft Preparation: H.M.K. Writing—Review and Editing: All authors. Visualization: H.M.K. Supervision: S.-H.H. All authors read and approved the final manuscript.

**Funding**
This research was supported by the Korea Medical Device Development Fund grant funded by the Korean government (Ministry of Science and ICT, Ministry of Trade, Industry and Energy, Ministry of Health & Welfare, Republic of Korea, Ministry of Food and Drug Safety) (Project Number: KMDF_PR_202000901_0006).

**Availability of data and materials**
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Catholic University of Korea (IRB No. KC20ID0966). Informed consent was waived by the IRB of Catholic University of Korea since this study was retrospective and blinding of the personal information in the data was performed.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea. 2 Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea. 3 Department of Urology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea. 4 Department of Urology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea. 5 Department of Urology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University, Seoul 06591, Korea. 6 Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4 SUPPL):1271–9. https://doi.org/10.1016/j.juro.2009.07.004.

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
2. Hong S; Won, Y.-J.; Lee, J. J.; Jung, K. W.; Kong, H.-J.; Im, J.-S.; Seo, H. G. Chromephi metabolism as an important pathway in RCC. Front Oncol. 2019;9(July):1–9. https://doi.org/10.3389/fonc.2019.00663.
3. Gandaglia G, Ravi P, Abdollah F, Abd-El-Barr AERM, Becker A, Popa I, Briganti A, Carakiewicz P, Tiran QD, Jewett MA, Sun M. Contemporary incidence and mortality rates of kidney cancer in the United States. J Can. Urol. Assoc. 2014, 8(7–8 August), 247–252. Doi:https://doi.org/10.5498/cuaj.1760.
4. Liu X, Zhang M, Liu X, Sun H, Guo Z, Tang X, Wang Z, Li J, Li H, Sun W, Zhang Y. Urine metabolomics for renal cell carcinoma (RCC) prediction: tryptophan metabolism as an important pathway in RCC. Front Oncol. 2019;9(july):1–9. https://doi.org/10.3389/fonc.2019.00663.
5. Ljungberg B, Gowen NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398–406. https://doi.org/10.1016/j.eururo.2010.06.032.
6. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4 SUPPL):1271–9. https://doi.org/10.1016/j.juro.2009.07.004.
7. Torpy JM, Lynm C, Glass RM. Kidney cancer. J Am Med Assoc. 2004;292(1):134. https://doi.org/10.1001/jama.292.1.134.
8. Jang HA, Kim JW, Byun SS, Hong SH, Kim YJ, Park YH, Yang KS, Cho S, Cheon J, Kang SH. Oncologic and functional outcomes after partial nephrectomy versus radical nephrectomy in T1b renal cell carcinoma: a multicenter, matched case-control study in Korean patients. Cancer Res. Treat. Off. J. Korean Cancer Assoc. 2016;48(2):612–20. doi:https://doi.org/10.4143/crt.2014.122.
9. Hollingsworth JM, Miller DC, Dargnau S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8. https://doi.org/10.1002/cncr.22600.
10. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the surveillance, epidemiology, and end results program. J Urol. 2006;176(6):2397–400. https://doi.org/10.1016/j.juro.2006.07.144.
11. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52. https://doi.org/10.1016/S0091-6749(03)00056-9.
12. Fuji Y, Ikeda M, Kurosawa K, Tabata M, Kainomot T, Hosoda C, Okane T. Different clinicopathologic features between patients who developed early and late recurrence following surgery for renal cell carcinoma. Int J Clin Oncol. 2015;20(4):802–7. https://doi.org/10.1007/s10147-014-0775-2.
13. Ljungberg B, Almardar I, Rasmusson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastasis after radical nephrectomy. BJU Int. 1999;84(4):405–11. https://doi.org/10.1046/j.1464-410X.1999.00202.x.
14. Kim SP, Weigh CJ, Leibovici BJ, Thompson RH, Costello BA, Cheville JC, Lohe CM, Boorjian SA. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urolology. 2011;78(5):1101–6. https://doi.org/10.1016/j.urology.2011.05.012.
15. Brookman-May S, May M, Shariat SF, Xylenas E, Stief C, Zigeuner R, Chromephi T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nuzi C, Fichche B, Truss M, Gilcher F, Pahemik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirono V, Longo N, Simonato A, Carnagni M, Gicara F. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE Score) to predict late recurrence based on a large multicenter database. Eur Urol, 2013(4):47–72. https://doi.org/10.1016/j.eururo.2012.06.030.
16. Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU Int. 2012;111(11):1533–8. https://doi.org/10.1111/j.1464-410X.2012.11246.x.
17. Miyao N, Naito S, Ozono S, Shinohara H, Masumori N, Igarashi T, Nakao M, Tsushima T, Senga Y, Horie S, Kanayama HO, Tokuda N, Kobayashi M. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urolology. 2011;77(2):379–84. https://doi.org/10.1016/j.jurology.2010.07.462.
18. Ha YS, Park YH, Kang SH, Hong SH, Hwang TK, Byun SS, Kim YJ. Predic‑tive factors for late recurrence in patients with stage T1 clear cell renal cell carcinoma: a multinational study. Can Genitourin Cancer. 2013;11(1):51–5. https://doi.org/10.1016/j.clgc.2012.08.008.
19. Mohammed MA, Abd Ghani MK, Hamed RI, Ibrahim DA. Review on Nasopharyngeal carcinoma: concepts, methods of analysis, segmentation, classification, prediction and impact: a review of the research literature. J Comput Sci. 2017;21:283–98. https://doi.org/10.1016/j.jcs.2017.03.021.
20. Mohammed MA, Ghani MKA, Hamed RI, Ibrahim DA. Analysis of an elec‑tronic methods for nasopharyngeal carcinoma: prevalence, diagnosis, challenges and technologies. J Comput Sci. 2017;21:241–54. https://doi.org/10.1016/j.jcs.2017.04.006.
21. Mohammed MA, Abd Ghani MK, Arunkumar N, Mostafa SA, Abdullah MK, Burhanuddin MA. Trainable model for segmenting and identifying nasopharyngeal carcinoma. Comput Electr Eng. 2018;71(March):372–87. https://doi.org/10.1016/j.compeleceng.2018.07.044.
22. Mohammed MA, Abd Ghani MK, Hamed RI, Ibrahim DA, Abdullah MK. Artificial neural networks for automatic segmentation and identification of nasopharyngeal carcinoma. J Comput Sci. 2017;21:263–74. https://doi.org/10.1016/j.jcs.2017.03.026.
23. Mohammed MA, Abd Ghani MK, Arunkumar N, Hamed RI, Mostafa SA, Abdullah MK, Burhanuddin MA. Decision support system for nasopharyngeal carcinoma discrimination from endoscopic images using artificial
neural network. J Supercomput. 2020;76(2):1086–104. https://doi.org/10.1007/s11227-018-2587-z.
24. Abdar M, Zomorodi-Moghaddam M, Zhou X, Gururajan R, Tao X, Barua PD, Gururajan R. A new nested ensemble technique for automated diagnosis of breast cancer. Pattern Recognit Lett. 2020;132:123–31. https://doi.org/10.1016/j.patrec.2018.11.004.
25. Chaunzva TL, Hosny A, Xu Y, Shafer A, Diao N, Lanutti M, Christiani DC, Mak RH, Aerts HJW. Deep learning classification of lung cancer histology using CT images. Sci Rep. 2021;11(1):1–12. https://doi.org/10.1038/s41598-021-84630-x.
26. Khan AH, Abbas S, Khan MA, Farooq U, Khan WA, Siddiqui SY, Ahmad A. Intelligent model for brain tumor identification using deep learning. Appl Comput Intell Soft Comput. 2022;2022. doi:https://doi.org/10.1155/2022/8104054.
27. Kim HM, Lee SJ, Park SJ, Choi PY, Hong SH. Machine learning approach to predict the probability of recurrence of renal cell carcinoma after surgery: prediction model development study. JMMR Med Inform. 2021;9(3):1–12. https://doi.org/10.2196/25635.
28. Mukherjee G, Bhattacharjee T, Ray H, Mitra K, Biswas DH, Debroy S, Bhowmick S, Chatterjee A, Bhattacharya D, Das D. Prediction of recurrence in non small cell lung cancer: analysis of TCGA data using outlier analysis and generalized matrix LQV. In: Proceedings - 2016 IEEE Congress Evolution Computation CEC 2016. 2016. 566–61. https://doi.org/10.1109/CEC.2016.773885.
29. Buynu SS, Hong SK, Lee S, Kook HR, Lee E, Kim HH, Kwak C, Koo JH, Jeong CW, Lee JY, Hong SH, Kim YJ, Ihwang EC, Kwon TG, Kim TH, Kang SH, Kim SH, Chung J. The establishment of KORCC (KOrean Renal Cell Carcinoma) database. Investig Clin Urol. 2016;57(1):50–7. https://doi.org/10.4111/icu.2016.57.1.30.
30. Li K, Zhang W, Lu Q, Fang X. An improved SMOTE imbalanced data classification method based on support degree. In: Proceedings - 2014 International Conference Identification, Information and Knowledge Internet Things, IIKI 2014. 2014. 34–38. doi:https://doi.org/10.1109/IIKI.2014.14.
31. Abdel-Hamid NB, ElGamrawy S, Desouky AEI, Arafat H. A dynamic spark-based classification framework for imbalanced big data. J. Grid Comput. 2018;16(4):607–26. https://doi.org/10.1007/s10723-018-9465-z.
32. Wang S, Li Z, Chiao W, Cao Q. Applying adaptive over-sampling technique based on data density and cost-sensitive SVM to imbalanced learning. In: Proceedings of the International Joint Conference Neural Networks. 2012. 10–15. doi:https://doi.org/10.1109/IJCNN.2012.6252696.
33. Xu Z, Shen D, Nie T, Kou Y. A hybrid sampling algorithm combining M-SMOTE and ENN based on random forest for medical imbalanced data. J Biomed Inform. 2019;2020(10):103.465. https://doi.org/10.1016/j.jbi.2020.103465.
34. Xu Z, Shen D, Nie T, Kou Y, Yin N, Han X. A cluster-based oversampling algorithm combining SMOTE and k-means for imbalanced medical data. Inf. Sci. (NY). 2021;572, 574–589. doi:https://doi.org/10.1016/j.ins.2021.02.056.
35. Zhang R, Ma J. An improved SVM method P-SVM for classification of remotely sensed data. Int J Remote Sens. 2008;29(20):6029–36. https://doi.org/10.1080/01431160802220151.
36. Thabata F, Abdelhamid N, Peebles D. A machine learning autism classification based on logistic regression analysis. Heal Inf Sci Syst. 2019;7(1):1–11. https://doi.org/10.1007/s13755-019-0073-5.
37. Peng NB, Zhang YX, Zhao YH. A SVM-KNN method for quasar-star classification. Sci. China Phys. Mech. Astron. 2013, 56(6):1227–34. https://doi.org/10.1007/s11433-013-5083-8.
38. Calders T, Verwer S. Three naive bayes approaches for discrimination-free classification. Data Min Knowl Discov. 2010;21(2):277–92. https://doi.org/10.1007/s10618-010-0190-x.
39. Probst P, Wright MN, Boulesteix AL. Hyperparameters and tuning strategies for random forest. Wiley Interdiscip. Rev: Data Min Knowl Discov. 2019, 9(3):1–15. doi:https://doi.org/10.1002/widm.1301.
40. Wang J, Li P, Ran R, Che Y, Zhou Y. A short-term photovoltaic power prediction model based on the gradient boost decision tree. Appl. Sci. 2018;8(5). doi:https://doi.org/10.3390/app8050689.
41. Freund Y, Schapire RE. A decision-theoretic generalization of online learning and an application to boosting. J Comput Syst Sci. 1997;55(1):119–39. https://doi.org/10.1007/s10618-018-0390-4.
42. Sahin EK. Assessing the predictive capability of ensemble tree methods for landslide susceptibility mapping using XGBoost, gradient boosting machine, and random forest. SN Appl. Sci. 2020;2(7):1–17. https://doi.org/10.1007/s42452-020-3060-1.
43. Sun Y, Ding S, Zhang Z, Jia W. An improved grid search algorithm to optimize SVR for prediction. Soft Comput. 2021;25(7):5633–44. https://doi.org/10.1007/s00500-020-04560-w.
44. Azodi CB, Tang J, ShiU SH. Opening the black box: interpretable machine learning for geneticists. Trends Genet. 2020;36(6):442–55. https://doi.org/10.1016/j.tig.2020.03.005.
45. Dianiya T, Geetha M, Kumar KS. Classification and regression trees with Gini index. Adv Math Sci J. 2020(9)(10):8237–47. doi:https://doi.org/10.37418/amsj.9.10.53.
46. Crispin PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, Leibovich BC. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7. https://doi.org/10.1016/j.juro.2008.07.047.
47. Abu-Ghanem Y, Powles T, Capitanio U, Beisland C, Järvinen P, Stewart GD, Gudmundsson ED, Lam TB, Marconi L, Fernandez-Pello S, Nisen H, Meijer RP, Volpe A, Ljungberg B, Klatte T, Dabestani S, Bex A. The impact of histological subtype on the incidence, timing, and patterns of recurrence in patients with renal cell carcinoma after surgery-results from RECUR consortium. Eur Urol Oncol. 2021;4(3):473–82. https://doi.org/10.1016/j.euo.2020.09.005.
48. Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–6. https://doi.org/10.1097/JTO.0b013e3181e1ced73d.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more biomedcentral.com/submissions